Revelation Biosciences Inc Ordinary Shares REVB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.82
- Day Range
- $0.80–0.83
- 52-Week Range
- $0.70–23.70
- Bid/Ask
- $0.82 / $0.83
- Market Cap
- $3.09 Mil
- Volume/Avg
- 54,928 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body’s innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 9
- Website
- https://www.revbiosciences.com
Valuation
|
Metric
|
REVB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.18 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
REVB
Financial Strength
|
Metric
|
REVB
|
|---|---|
Quick Ratio | 1.08 |
Current Ratio | 1.10 |
Interest Coverage | — |
Quick Ratio
REVB
Profitability
|
Metric
|
REVB
|
|---|---|
Return on Assets (Normalized) | −115.26% |
Return on Equity (Normalized) | −213.47% |
Return on Invested Capital (Normalized) | −213.47% |
Return on Assets
REVB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lxlqmlzcz | Systf | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bhctplk | Nysgmm | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dmjpdpfc | Hrmlqcd | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pbhfhtg | Mycbnl | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Vhvvfqgdb | Xjxyy | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Kvtydvb | Xszvt | $29.2 Bil | |||
| Moderna Inc
MRNA
| Yzhtrdyf | Dbhm | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Jnskftfgj | Svzg | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qtccxsrz | Wlyxygp | $13.2 Bil | |||
| Incyte Corp
INCY
| Bcslnpg | Fspjm | $13.0 Bil |
United States